Cutting edge oncology research progresses more quickly than anticipated

Redx Pharma reaches pre-clinical proof of concept stage with oncology lead

Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton’s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ?

Redx’s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers.

Could be a significant step in the potential advancement of CLL treatment.